A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation

Phase 1

Terminated

• Conditions: Metastatic Colorectal Cancer (CRC)
• Interventions: Drug: BI 1701963; Drug: Camptosar®

• Registration Number: NCT04627142
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

This study is open to adults with advanced bowel cancer (colorectal cancer) with a KRAS mutation. This is a study in people for whom previous treatment was not successful and surgery is not a treatment option.

The purpose of this study is to find the highest dose of BI 1701963 that people with bowel cancer can tolerate when taken together with a medicine called irinotecan. The study also tests whether BI 1701963 in combination with irinotecan is able to make tumours shrink. BI 1701963 may help to turn off KRAS. Activating KRAS mutations make tumours grow. Irinotecan is a medicine to treat bowel cancer.

Participants can stay in the study as long as they benefit from treatment and can tolerate it.

During this time, participants take BI 1701963 as tablet once a day and get irinotecan as infusion every two weeks. The doctors regularly monitor the size of the tumour. The doctors also collect information on any health problems of the participants.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2020-11-10
• Study First Submitted QC: 2020-11-12
• Study First Posted: 2020-11-13
• Study Start: 2020-11-23
• Primary Completion: 2022-01-18
• Study Completion: 2022-01-18
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-19
• Last Update Posted: 2022-04-20

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Patient must have a confirmed activating KRAS mutation in CRC tumour tissue by local test. Activating mutations include but are not limited to: KRAS mutations in exon 2 (G12, G13), exon 3 (A59, Q61) and exon 4 (K117, A146)

• Patients must have a histological or cytological diagnosis of CRC

• Patients must have received at least first-line chemotherapy (oxaliplatin/ 5-Fluorouracil (5-FU)/ capecitabine et al treatment failure) for unresectable locally advanced or metastatic CRC

• Must have at least one target lesion that can be accurately measured per RECIST version 1.1

• Must have Eastern Cooperative Oncology Group score of 0 or 1

• Must show adequate organ function defined as all of the following:

  1. Absolute neutrophil count (ANC) ≥1.5 x 109/L; haemoglobin ≥9.0 g/dL; platelets ≥100 x 109/L without the use of hematopoietic growth factors within 4 weeks of start of Trial medication.
  2. Total bilirubin ≤1.5 x Upper Limited of Normal (ULN), or ≤4 x ULN for patients who are known to have Gilbert's syndrome
  3. Creatinine ≤1.5 x ULN. If creatinine is >1.5 x ULN, patient is eligible if concurrent glomerular filtration rate (GFR) ≥30 mL/min (measured or calculated by CKD-EPI formula)
  4. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤3 x ULN if no demonstrable liver metastases, or otherwise ≤5 x ULN

• For patients participating in the combination dose escalation and expansion parts (Part B and C), must be eligible to receive treatment with irinotecan in accordance with the local label including Summary of Product Characteristics (SmPC), U.S. PI or Chinese Label

• Must be at least 18 years of age at screening

• Must have recovered from any previous therapy related toxicity to CTCAE grade ≤1 before the first dose (except for alopecia; stable sensory neuropathy must be CTCAE grade ≤2)

• Signed and dated written informed consent in accordance with good clinical practice and local legislation prior to admission to the trial

• further inclusion criteria apply

Read More

Exclusion Criteria

• Previous anticancer chemotherapy, anticancer immunotherapy, and/or other anticancer biologic therapy within 3 weeks of the first administration of trial drug. Previous anticancer hormonal therapy within 2 weeks of first administration of trial drug

• Previous treatment with a RAS, Mitogen-activated protein kinase (MAPK) or Son of Sevenless 1 (SOS1) targeting agent

• For patients participating in the combination dose escalation and expansion parts (Part B and C only): Previous treatment with irinotecan

• Radiotherapy within 4 weeks except as follows

  • Palliative radiotherapy to regions other than the chest is allowed up to 2 weeks prior to start of treatment
  • Single dose palliative radiotherapy for symptomatic metastasis within 2 weeks prior to start of treatment may be allowed but must be discussed with the sponsor

• Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of treatment or planned during the projected course of the trial, e.g. hip replacement

• Previous treatment with any investigational agent(s) or targeted treatment within 28 days prior to start of treatment

• Known history of hypersensitivity to any of the excipients of BI 1701963 tablets

• History or presence of cardiovascular abnormalities such as uncontrolled Hypertension, congestive heart failure New York Heart Association (NYHA) classification of ≥3, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the investigator; Myocardial infarction within 6 months prior to start of treatment

• Left ventricular ejection fraction (LVEF) <50%

• Congenital long QT prolongation syndrome or mean resting corrected QT interval (QTcF) >470 msec

• further exclusion criteria apply

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Expansion dose 1	BI 1701963	Part C: Combination therapy expansion part
Expansion dose 1	Camptosar®	Part C: Combination therapy expansion part
Expansion dose 2	BI 1701963	Part C: Combination therapy expansion part
Expansion dose 2	Camptosar®	Part C: Combination therapy expansion part

Primary Outcome Measures

Name	Time	Method
Number of patients experiencing DLTs in the MTD evaluation period	28 days	Combination dose escalation part (Part B)
Objective Response (OR) according to RECIST version 1.1	28 days per treatment cycle.	Combination therapy expansion part (Part C)
Maximum tolerated dose (MTD) based on the number of dose limiting toxicities (DLTs) in the MTD evaluation period	28 days	Combination dose escalation part (Part B)

Secondary Outcome Measures

Name	Time	Method
Area under the concentration time curve of BI 1701963 in plasma over the time interval from 0 to the last quantifiable plasma concentration (AUC0-tz)	28 days per treatment cycle.	Monotherapy safety run-in part (Part A)
Area under the concentration-time curve of BI 1701963 in plasma over the dosing interval τ at steady state (AUCτ(,ss))	28 days per treatment cycle.	Monotherapy safety run-in and combination dose escalation part (Part A+B)
Duration of objective response (DOR)	28 days per treatment cycle.	Combination therapy expansion part (Part C)
Number of patients with DLTs in the first treatment cycle	28 days	Monotherapy safety run-in part (Part A)
Maximum measured concentration of BI 1701963 in plasma (Cmax)	28 days per treatment cycle.	Monotherapy safety run-in part (Part A)
Maximum measured concentration of BI 1701963 in plasma at steady state over a uniform dosing interval tau (Cmax,ss)	28 days per treatment cycle.	Monotherapy safety run-in and combination dose escalation part (Part A+B)
Tumour shrinkage (in millimetres)	28 days per treatment cycle.	Combination therapy expansion part (Part C)
Progression-free survival (PFS)	Up to 6 months.	Combination therapy expansion part (Part C)
Number of patients experiencing grade ≥3 treatment-related AEs during the entire treatment period	28 days per treatment cycle.	Combination therapy expansion part (Part C)

Trial Locations

Locations (1)

Shanghai East Hospital, Tongji University China; 🇨🇳 Shanghai, China